Team Startupcity

• Dectrocel raises Rs 4 crore led by IAN Group’s BioAngels, with participation from PadUp Ventures and Vinners.
• DecXpert approved by CDSCO – one of only three AI diagnostic tools in India with regulatory clearance, delivering 98% accuracy and 10x faster interpretations.
• Expansion plans include scaling operations in India, entering global markets, and launching new AI tools for CT, MRI, PET-CT, and HPB diagnostics.
   

Dectrocel, a Lucknow-based healthtech startup building AI-powered diagnostic tools, has raised Rs 4 crore in a fresh funding round led  IAN Group-backed BioAngels, with participation from PadUp Ventures and Vinners. Notable IAN investors in this round include Nitin Zamre, Samir Kalia, and Mitesh Shah.

The company plans to deploy the capital to strengthen its commercial presence across India, enhance its self-learning multimodal AI platform, expand into global markets, and fast-track the rollout of upcoming AI tools for CT, MRI, PET-CT, and HPB diagnostic modules.

Dectrocel’s flagship product, DecXpert, is among only three AI-based diagnostic solutions approved by the Central Drugs Standard Control Organization (CDSCO) for clinical use in India. The platform delivers chest X-ray and CT-scan interpretations up to 10 times faster with 98% accuracy, directly addressing India’s acute radiologist shortage currently at a ratio of 1:125,000. This scarcity often results in diagnosis delays of 7–10 days and error rates reaching 40%, especially in tier-2 and smaller cities where early detection can be life-saving.

Also Read- L Catterton Raises $200Million in First Close of India Consumer Fund

The startup was founded ,Ankit Shukla, an AI-in-medicine expert from the University of Queensland and MS in Infectious Diseases from Duke Medical School, NUS Singapore; Saumya Shukla, a Doctorate in Public Health from SGPGIMS with an MBA from NUS and MS in Data Science from Harvard; and Nikhil Mishra, an IIT Kanpur researcher specializing in AI and machine learning in medicine.

Dectrocel’s mission is rooted in a personal tragedy the loss of a patient who went undiagnosed for months due to delayed X-ray interpretation, only to be detected at late-stage lung cancer. This experience shaped the founders’ vision to democratize access to accurate, expert-level diagnostics for every patient, regardless of geography or income.